The immunopathogenesis and management of Kawasaki syndrome

Arthritis and Rheumatism

Volumn 41, Issue 9, 1998, Pages 1538-1547

  Leung, Donald Y M ^a   Schlievert, Patrick M ^b   Meissner, H Cody ^c  

^a NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c TUFTS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; BACTERIAL ANTIGEN; CORTICOSTEROID; DIGITALIS; DIURETIC AGENT; IMMUNOGLOBULIN; METHYLPREDNISOLONE; STREPTOKINASE; SUPERANTIGEN;

ANEURYSM; CARDIOVASCULAR DISEASE; CLINICAL FEATURE; CORONARY ARTERY DISEASE; DIFFERENTIAL DIAGNOSIS; HUMAN; IMMUNOPATHOGENESIS; INTRAVENOUS DRUG ADMINISTRATION; LABORATORY DIAGNOSIS; LONG TERM CARE; MUCOCUTANEOUS LYMPH NODE SYNDROME; MYOCARDITIS; PERICARDIAL EFFUSION; PRIORITY JOURNAL; REVIEW; STAPHYLOCOCCUS AUREUS;

CHILD; CHILD, PRESCHOOL; HUMANS; INFANT; INFANT, NEWBORN; MUCOCUTANEOUS LYMPH NODE SYNDROME;

EID: 0031681187     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/1529-0131(199809)41:9<1538::AID-ART3>3.0.CO;2-M     Document Type: Review

References (79)

1. Kawasaki T. Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes in children: clinical observations of 50 cases. Jpn J Allergol 1967;16:178-222.
2. Kawasaki T, Kosaki F, Okawa S, Shigematsu I, Yanagawa H. A new infantile acute febrile mucocutaneous lymph node syndrome (MLNS) prevailing in Japan. Pediatrics 1974;54:271-6.
3. Yanagawa H, Nakamura Y, Yashiro M, Fujita Y, Nagai M, Kawasaki T, et al. A nationwide incidence survey of Kawasaki disease in 1985-1986 in Japan. J Infect Dis 1988;158:1296-301.
4. Taubert K, Rowley A, Shulman S. A nationwide survey of Kawasaki disease and acute rheumatic fever. J Pediatr 1991;119:279-82.
5. Furusho K, Kamiya T, Nakano H, Kiyosawa N, Shinomiya K, Hayashidera T, et al. High dose intravenous gammaglobulin for Kawasaki disease. Lancet 1984;2:1055-8.
6. Newburger JW, Takahashi M, Burns JC, Beiser AS, Chung KJ, Duffy CE, et al. The treatment of Kawasaki syndrome with intravenous gammaglobulin. N Engl J Med 1986;315:341-7.
7. Newburger JW, Takahashi M, Beiser AS, Burns JC, Bastian J, Chung KJ, et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N Engl J Med 1991;324:1633-9.
8. Rowley AH, Duffy CE, Shulman ST. Prevention of giant coronary artery aneurysms in Kawasaki disease by intravenous gamma globulin therapy. J Pediatr 1989;114:1065-6.
9. Joffe A, Kabani A, Jadavji T. Atypical and complicated Kawasaki disease in infants: do we need criteria? West J Med 1995;162: 322-7.
10. Rowley AH, Gonzalez-Crussi F, Gidding SS, Duffy CE, Shulman ST. Incomplete Kawasaki disease with coronary involvement. J Pediatr 1987;110:409-13.
11. Rauch AM. Kawasaki syndrome: critical review of U.S. epidemiology. Prog Clin Biol Res 1987;250:33-44.
12. Shulman ST, De Inocencio J, Hirsch R. Kawasaki disease. Pediatr Clin North Am 1995;42:1205-22.
13. Dajani AS, Taubert KA, Gerber MA, Shulman ST, Ferrieri P, Freed M, et al. Diagnosis and therapy of Kawasaki disease in children. Circulation 1993;87:1776-80.
14. Burns JC, Wiggins JW, Toews WH, Newburger JW, Leung DYM, Wilson H, et al. The clinical spectrum of Kawasaki syndrome in infants less than six months of age. J Pediatr 1986;109:759-63.
15. Friter BS, Lucky AW. The perineal eruption of Kawasaki syndrome. Arch Dermatol 1988;124:1805-10.
16. Burns JC, Joffe L, Sargent RA, Glode MP. Anterior uveitis associated with Kawasaki syndrome. Pediatr Infect Dis 1985;4: 258-61.
17. Hicks RV, Melish ME. Kawasaki disease. Pediatr Clin North Am 1986;33:1151-75.
18. Kato H, Ichinose E, Kawasaki T. Myocardial infarction in Kawasaki disease: clinical analyses in 195 cases. J Pediatr 1986;108: 923-7.
19. Yutani C, Okano K, Kamiya T, Oguchi K, Kozuka T, Ota M, et al. Histopathological study on right endomyocardial biopsy of Kawasaki disease. Br Heart J 1980;43:589-92.
20. Kato H, Ichinose E, Yoshioka F, Takcchi T, Matsunaga S, Suzuki K, et al. Fate of coronary aneurysms in Kawasaki disease: serial coronary angiography and long-term follow-up study. Am J Cardiol 1982;49:1758-66.
21. Fukushige J, Nihill MR, McNamara DG. Spectrum of cardiovascular lesions in mucocutaneous lymph node syndrome: analysis of eight cases. Am J Cardiol 1980;45:98-107.
22. Meissner HC, Leung DYM. Kawasaki syndrome. In: Gorbach SL, Bartlett JG, Black NR, editors. Infectious diseases. New York: WB Saunders; 1997. p. 1662-6.
23. Fujiwara H, Hamashima Y. Pathology of the heart in Kawasaki's disease. Pediatrics 1978;61:100-7.
24. Hirose S, Hamashima Y. Morphological observations on the vasculitis in the mucocutaneous lymph node syndrome: a skin biopsy study of 27 patients. Eur J Pediatr 1978;129:17-27.
25. Terai M, Kohno Y, Namba M, Umemiya T, Niwa K, Nakajima H, et al. Class II major histocompatibility antigen expression on coronary arterial endothelium in a patient with Kawasaki disease. Hum Pathol 1990;21:231-4.
26. Leung DYM, Cotran RS, Kurt-Jones EA. Burns JC, Newburger JW, Pober JS. Endothelial activation and high interleukin-1 secretion in the pathogenesis of acute Kawasaki disease. Lancet 1990; 335:410-1.
27. Leung DYM, Siegel RL, Krensky A, Grady S, Meade R, Reinherz EL. Immunoregulatory abnormalities in mucocutaneous lymph node syndrome. Clin Immunol Immunopathol 1982;23:100-12.
28. Leung DYM, Chu ET, Wood N, Grady S, Meade R, Geha RS. Immunoregulatory T cell abnormalities in mucotaneous lymph node syndrome. J Immunol 1983;130:2002-4.
29. Furukawa S, Matsubara T, Jujoh K, Yone K, Sugawara T, Sasai K, et al. Peripheral blood monocyte/macrophage and serum tumor necrosis factor in Kawasaki disease. Clin Exp Immunol 1988;48: 247-51.
30. Maury CP, Salo E, Pelkonen P. Elevated circulating tumor necrosis factor-alpha in patients with Kawasaki disease. J Lab Clin Med 1989;113:651-4.
31. Ueno Y, Takano N, Kanegane H, Yokoi T, Yachie A, Miyawaki T, et al. The acute phase nature of interleukin 6: studied in Kawasaki disease and other febrile illness. Clin Exp Immunol 1989;76:337-42.
32. Rowley AH, Shulman ST, Preble OT, Poiesz BJ, Ehrlich GD, Sullivan JR. Serum interferon concentrations and retroviral serology in Kawasaki syndrome. Pediatr Infect Dis J 1988;7:663-6.
33. Maury CP, Salo E, Pelkonen P. Circulating interleukin-1 beta in patients with Kawasaki disease. N Engl J Med 1988;319:1670-1.
34. Falcini F. Nerve growth factor circulating levels are increased in Kawasaki disease: correlation with disease activity and reduced angiotensin converting enzyme levels. J Rheumatol 1996;23:1798-802.
35. Matsubara T, Furukawa S, Motohashi T, Okumura K, Yabuta K. Soluble CD23 antigen in Kawasaki disease and other acute febrile illnesses. Eur J Pediatr 1995;154:826-9.
36. Lang BA, Silverman ED, Laxer RM, Lau AS. Spontaneous tumor necrosis factor production in Kawasaki disease. J Pediatr 1989; 115:939-43.
37. Mantovani A, Dejana E. Cytokines as communication signals between leukocytes and endothelial cells. Immunol Today 1989; 10:370-5.
38. Leung DYM, Geha RS, Newburger JW, Burns JC, Fiers W, Lapierre LA, et al. Two monokines, interleukin 1 and tumor necrosis factor, render cultured vascular endothelial cells susceptible to lysis by antibodies circulating during Kawasaki Syndrome. J Exp Med 1986;164:1958-72.
39. Leung DYM, Collins T, Lapierre L, Geha R, Pober J. IgM antibodies in the acute phase of Kawasaki syndrome lyse cultured vascular endothelial cells stimulated by y interferon. J Clin Invest 1986;77:1428-35.
40. Leung DYM, Burns J, Newhurger J, Geha RS. Reversal of immunoregulatory abnormalities in Kawasaki syndrome by intravenous gammaglobulin. J Clin Invest 1987;79:468-72.
41. Kotzin BL, Leung DYM, Kappler J, Marrack P. Superantigens and human disease. Adv Immunol 1993;54:99-166.
42. Abe J, Kotzin BL, Jujo K, Melish ME, Glode MP, Kohsaka T, et al. Selective expansion of T cells expressing T-cell receptor variable regions V beta 2 and V beta 8 in Kawasaki disease. Proc Natl Acad Sci U S A 1992;89:4066-70.
43. Choi Y, Lafferty JA, Clements JR, Todd JK, Gelfand EW, Kappler J, et al. Selective expansion of T cells expressing Vβ2 in toxic shock syndrome. J Exp Med 1990;172:981-4.
44. Curtis N, Zheng R, Lamb JR, Levin M. Evidence for a superantigen mediated process in Kawasaki disease. Arch Dis Child 1995;72:308-11.
45. Abe J, Kotzin BL, Meissner C, Melish ME, Takahashi M, Fulton D, et al. Characterization of T cell repertoire changes in acute Kawasaki disease. J Exp Med 1993;177:791-6.
46. Yamashiro Y, Nagata S, Oguchi S, Shimizut T. Selective increase of Vβ2+ T cells in the small intestinal mucosa in Kawasaki disease. Pediatr Res 1996;39:264-6.
47. Leung DYM, Giorno R, Kazemi LV, Flynn PA, Bussel JB. Evidence for superantigen involvement in cardiovascular injury due to Kawasaki syndrome. J Immunol 1995;155:5018-21.
48. Pietra BA, De Inocencio J, Giannini EH, Hirsch R. TCR V beta family repertoire and T cell activation markers in Kawasaki disease. J Immunol 1994;153:1881-8.
49. Sakaguchi M, Kato H, Nishiyori A, Sagawa K, Itoh K. Characterization of CD4+ T helper cells in patients with Kawasaki disease (KD): preferential production of tumour necrosis factor-alpha (TNF-alpha) by V beta 2- or V beta 8-CD4+ T helper cells. Clin Exp Immunol 1995;99:276-82.
50. Choi IH, Chwae YJ, Shim WS, Kim DS, Kwon DH, Kim JD, et al. Clonal expansion of CD8+ T cells in Kawasaki disease. J Immunol 1997;159:481-6.
51. Leung DYM, Gately M, Trumble A, Ferguson-Darnell B, Schlievert PM, Picker LJ. Bacterial superantigens induce T cell expression of the skin-selective homing receptor, the cutaneous lymphocyte-associated antigen (CLA). J Exp Med 1995;181:747-53.
52. McCormack JE, Callahan JE, Kappler J, Marrack PC. Profound deletion of mature T cells in vivo by chronic exposure to exogenous superantigen. J Immunol 1993;150:3785-92.
53. Leung DYM, Sullivan KE, Brown-Whitehorn TF, Fehringer AP, Allen S, Finkel TH, et al. Association of toxic shock syndrome toxin- and exoliative toxin-secreting Staphylococcus aureus with Kawasaki syndrome complicated by coronary artery disease. Pediatr Res 1997;42:268-72.
54. Leung DYM, Meissner HC, Fulton DR, Murray DL, Kotzin BL, Schlievert PM. Toxic shock syndrome toxin-secreting Staphylococcus aureus in Kawasaki syndrome. Lancet 1993;342:1385-8.
55. Konishi N, Baba K, Abe J, Maruko T, Waki K, Takeda N, et al. A case of Kawasaki disease with coronary artery aneurysms documenting Yersinia pseudotuberculous infection. Acta Pediatr 1997; 86:661-4.
56. Wiesenthal AM, Todd JK. Toxic shock syndrome in children aged 10 years or less. Pediatrics 1984;74:112-7.
57. Gamillscheg A, Zobel G, Karpf EF, Dacar D, Beitzke A, Stein JI, et al. Atypical presentation of Kawasaki disease in an infant. Pediatr Cardiol 1993;14:223-6.
58. Davies HD, Kirk V, Jadavji T, Kotzin BL. Simultaneous presentation of Kawasaki disease and toxic shock syndrome in an adolescent male. Pediatr Infect Dis J 1996;15:1136-8.
59. Leung DYM, Meissner HC, Fulton DR, Quimby F, Schlievert PM. Superantigens in Kawasaki disease. Clin Immunol Immunopathol 1996;17:385-96.
60. Koren G, Rose V, Lavi S, Rowe R. Probable efficacy of high-dose salicylates in reducing coronary involvement in Kawasaki disease. JAMA 1985;254:767-9.
61. Newburger JW, Sanders SP, Burns JC, Parness IA, Beiser AS, Colan SD. Left ventricular contractility and function in Kawasaki syndrome: effect of intravenous gamma-globulin. Circulation 1989;79:1237-46.
62. Durongpisitkul K, Gururaj VJ, Part JM, Martin CF. The prevention of coronary artery aneurysm in Kawasaki disease: a meta-analysis on the efficacy of aspirin and immunoglobulin treatment. Pediatrics 1995;96:1057-61.
63. Koren G, Lavi S, Rose V, Rowe R. Kawasaki disease: review of risk factors for coronary aneurysms. J Pediatr 1986;108:388-92.
64. Kato H, Koike S, Yokoyama T. Kawasaki disease: effect of treatment on coronary artery involvement. Pediatrics 1979;63: 175-9.
65. Wright DA, Newburger JW, Baker A, Sundel RP. Treatment of immune globulin-resistant Kawasaki disease with pulsed doses of corticosteroids. J Pediatr 1996;128:146-9.
66. Takei S, Arora YK, Walker SM. Intravenous immunoglobulin contains specific antibodies inhibitory to activation of T cells by staphylococcal toxin superantigens. J Clin Invest 1993;91:602-7.
67. Hauk PJ, Wenzel SE, Trumble AE, Strickland I, Szefler SJ, Leung DYM. Increased T cell receptor BV8+T cells in bronchoalveolar lavage of poorly controlled asthmatics: a potential role for microbial superantigens [abstract]. J Allergy Clin Immunol 1998;101: 977A.
68. FitzGerald GA. Dipyridamole. N Engl J Med 1987;316:1247-57.
69. Kitamura S, Kawachi K, Oyama C, Miyagi Y, Morita R, Koh Y, et al. Severe Kawasaki heart disease treated with an internal mammary artery graft in pediatric patients: a first successful report. J Thorac Cardiovasc Surg 1985;89:860-6.
70. Takahashi M, Mason W, Lewis AB. Regression of coronary aneurysms in patients with Kawasaki syndrome. Circulation 1987; 75:387-94.
71. Kato H, Sugimura T, Akagi T, Sato N, Hashino K, Maeno Y, et al. Long term consequences of Kawasaki disease: a 10-21 year follow-up study of 594 patients. Circulation 1996;94:1379-85.
72. Nakano H, Ueda K, Saito A, Nojima K. Repeated quantitative angiograms in coronary arterial aneurysm in Kawasaki disease. Am J Cardiol 1985;56:846-51.
73. Tatara K, Kusakawa S. Long-term prognosis of giant coronary aneurysm in Kawasaki disease: an angiograph, study. J Pediatr 1987;111:705-10.
74. Checchia PA, Pahl E, Shaddy RE, Shulman ST. Cardiac transplantation for Kawasaki disease. Pediatrics 1997;100:695-9.
75. Tanaka N, Naoe S, Masuda H, Ueno T. Pathological study of sequelae of Kawasaki disease (MCLS): with special reference to the heart and coronary arterial lesions. Acta Pathol Jpn 1986;6: 1513-27.
76. Matsumura K, Okudas Y, Ito T, Hirano T, Takeda K, Yamaguchi N. Coronary angiography of Kawasaki disease with the coronary vasodilator dipyridamole: assessment of distensibility of affected coronary arterial wall. Angiology 1988;39:141-7.
77. Dhillon R, Clarkson P, Donald AE, Powe AJ, Nash M, Novelli V, et al. Endothelial dysfunction late after Kawasaki disease. Circulation 1996;94:2103-6.
78. Melish ME, Parsonette J, Marchette N, and the U.S.-Japan Multicenter KS Study Group. Kawasaki syndrome is not caused by toxic shock syndrome toxin-1+ Staphylococci [abstract]. Pediatr Res 1994;35:187.
79. Terai M, Miwa K, Williams T, Kabat W, Fukuyama M, Okajima Y, et al. The absence of evidence of staphylococcal toxin involvement in the pathogenesis of Kawasaki disease. J Infect Dis 1995;172: 558-61.